Literature DB >> 33284867

Research progress of ulinastatin in the treatment of liver diseases.

Shangping Fang1, Pengfei Li1, Chenxu Zhu1, Xiaoxiao Han1, Pengju Bao1, Wenjun Guo2.   

Abstract

Ulinastatin (UTI) is a trypsin inhibitor observed in urine. UTI can treat some diseases by inhibiting the broad-spectrum hydrolysis activity of various enzymes and other pharmacological effects. UTI can widely treat pancreatitis, systemic multiple organ dysfunction syndrome, circulatory failure, and toxic shock clinically. The liver is a major metabolic organ of the human body. Various biological metabolic reactions require the liver's participation. When various physical and chemical factors drive the body, it will damage the liver to varying degrees. As a clinically effective drug, UTI is also known to treat some liver diseases. This article mainly describes UTI's research progress in treating septic liver injury, hepatitis, liver fibrosis, autoimmune liver disease with liver failure, and liver ischemia-reperfusion injury. IJCEP
Copyright © 2020.

Entities:  

Keywords:  Ulinastatin; an autoimmune liver disease with liver failure; hepatic fibrosis; hepaticischemia-reperfusion injury; hepatitis; septic liver injury

Year:  2020        PMID: 33284867      PMCID: PMC7716140     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  55 in total

1.  Role of Ulinastatin, a trypsin inhibitor, in severe acute pancreatitis in critical care setting: A retrospective analysis.

Authors:  Jui Yeshavant Lagoo; Moses Charles D'Souza; Anandajith Kartha; Appanervanda Muthanna Kutappa
Journal:  J Crit Care       Date:  2018-01-31       Impact factor: 3.425

2.  [Effect of ulinastatin on serum levels of tumor necrosis factor-α, P-selectin, and thrombin-antithrombin complex in young rats with sepsis].

Authors:  Yun Liu; Xing-Heng Wu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-02

3.  Ulinastatin ameliorates LPS‑induced pulmonary inflammation and injury by blocking the MAPK/NF‑κB signaling pathways in rats.

Authors:  Minjie Ju; Hongyu He; Song Chen; Yimei Liu; Yujing Liu; Simeng Pan; Yijun Zheng; Lizhen Xuan; Duming Zhu; Zhe Luo
Journal:  Mol Med Rep       Date:  2019-08-06       Impact factor: 2.952

Review 4.  Shock Etiologies and Fluid Management in Liver Failure.

Authors:  Emmanuel Weiss; Catherine Paugam-Burtz; Samir Jaber
Journal:  Semin Respir Crit Care Med       Date:  2018-11-28       Impact factor: 3.119

5.  Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis.

Authors:  Na Huang; Fei Wang; Yingwei Wang; Jiong Hou; Jinbao Li; Xiaoming Deng
Journal:  J Surg Res       Date:  2012-11-09       Impact factor: 2.192

6.  Plasma and urine levels of urinary trypsin inhibitor in patients with chronic liver diseases and hepatocellular carcinoma.

Authors:  Shi De Lin; Ryujin Endo; Hidekatsu Kuroda; Koryo Kondo; Yoshiaki Miura; Yasuhiro Takikawa; Akinobu Kato; Kazuyuki Suzuki
Journal:  J Gastroenterol Hepatol       Date:  2004-03       Impact factor: 4.029

Review 7.  Ulinastatin - a newer potential therapeutic option for multiple organ dysfunction syndrome.

Authors:  Sarjana S Atal; Shubham Atal
Journal:  J Basic Clin Physiol Pharmacol       Date:  2016-03

8.  Protective effect of ulinastatin combined with dexmedetomidine on lung injury after cold ischemia-reperfusion in rats.

Authors:  G Wang; J-Y Li; Y-Q Weng; M Ding; H-L Yu; Q Wang; H-C Ren; R-B Xu; W-L Yu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-09       Impact factor: 3.507

9.  Ulinastatin suppresses endoplasmic reticulum stress and apoptosis in the hippocampus of rats with acute paraquat poisoning.

Authors:  Hai-Feng Li; Shi-Xing Zhao; Bao-Peng Xing; Ming-Li Sun
Journal:  Neural Regen Res       Date:  2015-03       Impact factor: 5.135

10.  Ulinastatin preconditioning attenuates inflammatory reaction of hepatic ischemia reperfusion injury in rats via high mobility group box 1(HMGB1) inhibition.

Authors:  Ying Tong; Zhaohui Tang; Tian Yang; Yuting Yang; Liqun Yang; Weixing Shen; Weixin Chen
Journal:  Int J Med Sci       Date:  2014-02-11       Impact factor: 3.738

View more
  3 in total

1.  Somatostatin plus Ulinastatin in the Treatment of Severe Acute Pancreatitis and Its Effect on Serum Cytokine Levels.

Authors:  Li Yang; Zhibin Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-09       Impact factor: 2.650

2.  Ulinastatin promotes macrophage efferocytosis and ameliorates lung inflammation via the ERK5/Mer signaling pathway.

Authors:  Jinju Li; Rongge Shao; Qiuwen Xie; Ke Qin; ShaoPeng Ming; Yongguo Xie; XueKe Du
Journal:  FEBS Open Bio       Date:  2022-07-11       Impact factor: 2.792

3.  Analysis of transcriptome characteristics of UTI therapy for cerebral injury after CA/ROSC based on RNA-seq technique.

Authors:  Xiaojie Bai; Mingya Yang; Tiantian Zhu; Jun Xu; Wei Wang; Yuanyuan He; Yu Liu; Xingxing Li; Miao He; Tao Meng; Zhenzhen Wang; Hong Zhang; Lixin Zhu
Journal:  Iran J Basic Med Sci       Date:  2022-06       Impact factor: 2.532

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.